A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia

Sponsor
Bristol-Myers Squibb (Industry)
Overall Status
Completed
CT.gov ID
NCT00002067
Collaborator
(none)
14

Study Details

Study Description

Brief Summary

To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients with cachexia. To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8 ratio, and total lymphocytes.

Condition or Disease Intervention/Treatment Phase
  • Drug: Megestrol acetate
Phase 3

Study Design

Study Type:
Interventional
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Phase III Randomized Double-Blind Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Patient must have:
    • Confirmed diagnosis of AIDS (CDC definition).

    • Documented weight loss or anorexia.

    • Life expectancy = or > 20 weeks.

    • The perception that the weight loss is a detriment to their well-being.

    • Ability to provide informed consent, read and write English.

    Exclusion Criteria

    Co-existing Condition:
    Patients with the following conditions are excluded:
    • Dementia or evidence of mental incompetence which would preclude compliance with the protocol.

    • Severe diarrhea defined as 5 or more watery stools per day for at least 7 days.

    • Active uncontrolled systemic infections at the start of treatment.

    • Patients may not be entered for at least 2 weeks after acute infection.

    • Clinical or radiologic evidence of ascites or pleural effusions.

    Patients with the following are excluded:
    • Obstruction to food intake or impaired digestive/absorptive functions.

    • Contraindications to megestrol acetate (poorly controlled hypertension or heart failure or deep vein thrombosis).

    • Inability to consent or be available for close follow-up.

    • Active systemic infections at the start of treatment.

    • Clinical or radiologic evidence of ascites or pleural effusions.

    • Patients who have been hospitalized or have suffered an exacerbation of their illness associated with weight loss within the past 2 weeks are excluded.

    • Menstruating female patients are excluded.

    Prior Medication:
    Excluded:
    • Corticosteroids.

    • Anabolic steroids.

    • Marijuana.

    • Megestrol acetate.

    • Patients who have been started on zidovudine (AZT) within 8 weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.)

    Patients may not be started on any therapy designed to treat the underlying HIV infection or which may have a major impact on appetite and/or weight gain.

    • Patients who have been started on zidovudine (AZT) within 8 weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.)

    History of substance abuse and questionable current and future abstinence.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dr Mark Goldstein Los Angeles California United States 90048
    2 Summitt Med Ctr / San Francisco Gen Hosp Oakland California United States 94609
    3 Palo Alto Veterans Adm Med Ctr / Stanford Univ Palo Alto California United States 94304
    4 Eisenhower Med Ctr Rancho Mirage California United States 92270
    5 UCD Med Ctr Sacramento California United States 95817
    6 San Francisco AIDS Clinic / San Francisco Gen Hosp San Francisco California United States 941102859
    7 San Francisco Veterans Administration Med Ctr San Francisco California United States 94121
    8 Denver Public Health Dept Denver Colorado United States 80204
    9 Miami Veterans Administration Med Ctr Miami Florida United States 33125
    10 Univ of South Florida Tampa Florida United States 33612
    11 Northwestern Univ Med School Chicago Illinois United States 60611
    12 Mem Sloan - Kettering Cancer Ctr New York New York United States 10021
    13 SUNY / Health Sciences Ctr at Syracuse Syracuse New York United States 13210
    14 Northwest Family Ctr at the Harbor View Med Ctr Seattle Washington United States 98104

    Sponsors and Collaborators

    • Bristol-Myers Squibb

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002067
    Other Study ID Numbers:
    • 025B
    • MEG8809
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Oct 2, 2007
    Last Verified:
    Oct 1, 2007

    Study Results

    No Results Posted as of Oct 2, 2007